文献速递关节外科

两期翻修关节成形术再植入时α-防御素阳性与1年感染无关

Positive Alpha-defensin at Reimplantation of a Two-stage Revision Arthroplasty Is Not Associated with Infection at 1 Year.
PubMed 文献 · Clin Orthop Relat Res · 2019-01-01

这项多中心回顾性研究纳入69例(43膝、26髋)接受两期翻修并留置骨水泥间隔器的假体周围感染患者,以Delphi持续感染标准为金标准,评估滑液α-防御素-1(AD-1)检测在再植入时判断感染是否清除的价值。AD-1敏感性为7%(95%CI,0.2-34),总体准确率73%(95%CI,60-83),AUC为0.5(95%CI,0.3-0.6);AD-1与MSIS标准的c-index分别为0.519与0.518,二者差值-0.001(95%CI,-0.09至0.09;P=0.99)。作者建议不常规使用AD-1。

要点

  • 再植入时滑液AD-1检测敏感性仅7%(95%CI,0.2-34),总体准确率73%(95%CI,60-83)。
  • AD-1的AUC为0.5(95%CI,0.3-0.6),与MSIS标准c-index差值-0.001(95%CI,-0.09至0.09;P=0.99)。
  • 作者建议不常规使用AD-1,除非未来研究显示其更有效。

核心结论

  • 再植入时滑液AD-1阳性与两期翻修关节成形术治疗假体周围感染后1年持续感染相关性差。
  • 作者建议不常规使用AD-1,除非未来研究显示该检测比本研究所见更有效。

研究设计与样本

  • 多中心回顾性收集2014年5月至2016年7月间接受两期翻修关节成形术患者的数据。
  • 纳入既往确诊假体周围感染、接受骨水泥间隔器、完成二期手术、具备MSIS标准数据和滑液AD-1检测、且随访至少1年的患者。
  • 共69例(43膝、26髋)符合全部标准;研究期间AD-1使用指征因外科医生而异。

主要发现

  • AD-1检测1年感染清除的敏感性为7%(95%CI,0.2-34),总体准确率为73%(95%CI,60-83),AUC为0.5(95%CI,0.3-0.6)。
  • AD-1对Delphi持续感染标准的c-index为0.519(95%CI,0.44-0.60)。
  • MSIS标准对Delphi持续感染标准的c-index为0.518(95%CI,0.49-0.54)。
  • MSIS标准与AD-1的对比估计值为-0.001(95%CI,-0.09至0.09;P=0.99),两者无差异。

关键数值与推荐

  • 以Delphi持续感染标准为金标准计算AD-1的敏感性、特异性、阳性与阴性预测值、准确率及AUC(95%CI)。
  • 使用Delphi持续感染标准分别计算AD-1与MSIS标准的c-index及其Wald 95%CI和ROC曲线。
  • 采用DeLong非参数法比较AD-1与MSIS标准的c-index。

临床怎么用

  • 作者建议不常规使用AD-1,除非未来研究显示该检测比本研究所见更有效。

局限性

  • 研究为回顾性收集数据。
  • 无法确定所有研究机构中有多少患者接受了检测但不符合全部标准而无法纳入研究。
  • 研究期间AD-1使用指征因外科医生而异。
  • 证据等级为Level IV,诊断性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diagnosing periprosthetic joint infection (PJI) represents a challenge that relies on multiple clinical and laboratory criteria that may not be consistently present. The synovial alpha-defensin-1 (AD-1) test has been shown to correlate accurately with the Musculoskeletal Infection Society (MSIS) criteria for the diagnosis of PJI, however, its association with persistent PJI has not been elucidated in the setting of patients receiving antibiotic spacers during second-stage reimplantation. Applying a Delphi-based consensus to define successful eradication of PJI offers an opportunity to test the utility of AD-1 in this setting. QUESTIONS/PURPOSES: (1) Can the AD-1 test determine whether infection has been controlled using the Delphi criteria for persistent PJI as a surrogate for infection eradication during two-stage revision for PJI treatment with a spacer? (2) How does the performance of the AD-1 test compare with the MSIS criteria? METHODS: This was a multicenter analysis of retrospectively collected data on patients who underwent a two-stage revision arthroplasty between May 2014 and July 2016. We included patients who had a previously confirmed PJI and received a cement spacer, underwent the second stage, had MSIS criteria data and a synovial fluid AD-1 test, and had a minimum followup of 1 year. We were unable to determine for all study sites how many patients had the test but did not meet all the criteria and so could not be studied; however, we were able to identify 69 patients (43 knees, 26 hips) who met all criteria. During the period in question, indications for use of AD-1 varied by surgeon; however, during that time, in general if a surgeon ordered it as part of the initial workup, the test would have been repeated before the second-stage reimplantation procedure. To assess the validity of AD-1 against persistence of PJI criteria at 1 year, the following were calculated using the Delphi criteria for persistent PJI as the gold standard: sensitivity, specificity, positive and negative predictive values, accuracy, and area under the curve (AUC) with 95% confidence intervals (CIs). Concordance index (c-index) and its Wald 95% CI with receiver operating characteristic (ROC) curve were calculated in relation to Delphi criteria for persistent PJI using AD-1 and then MSIS criteria. The two c-indices of AD-1 and MSIS were compared using the DeLong nonparametric approach. RESULTS: The AD-1 test showed poor sensitivity (7%; 95% CI, 0.2-34), and poor overall accuracy (73%; 95% CI, 60-83; AUC = 0.5; 95% CI, 0.3-0.6) in detecting infection eradication at 1 year. The c-index for AD-1 versus Delphi criteria for persistent PJI was 0.519 (95% CI, 0.44-0.60), and the c-index for MSIS criteria versus Delphi criteria for persistent PJI was 0.518 (95% CI, 0.49-0.54), suggesting the weak diagnostic abilities of these models. The contrast estimate between MSIS criteria and AD-1 were not different from one another at -0.001 (95% CI%, -0.09 to 0.09; p = 0.99). CONCLUSIONS: We found that a positive synovial fluid AD-1 test correlated poorly with the presence of persistent infection 1 year after two-stage revision arthroplasty for PJI. For this reason, we recommend against the routine use of AD-1 in patients with cement spacers, until or unless future studies demonstrate that the test is more effective than we found it to be. LEVEL OF EVIDENCE: Level IV, diagnostic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Samuel LT, Sultan AA, Kheir M, et al. Positive Alpha-defensin at Reimplantation of a Two-stage Revision Arthroplasty Is Not Associated with Infection at 1 Year. Clin Orthop Relat Res. 2019. PMID: 30811358. doi:10.1097/CORR.0000000000000620

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。